Intraductal tubular adenomas (pyloric gland-type) of the pancreas: clinicopathologic features are similar to gastric-type intraductal papillary mucinous neoplasms and different from intraductal tubulopapillary neoplasms

Xiaoyan Chang, Ying Jiang, Ji Li and Jie Chen*

Abstract

Background: Intraductal tubular adenoma of the pancreas, pyloric gland type (ITA), is an infrequent intraductal benign lesion located in the main duct and large branch duct of the pancreas. The purpose of this report is to introduce seven new cases and to compare their clinicopathologic features and KRAS mutations to gastric-type intraductal papillary mucinous neoplasms (IPMNs) and intraductal tubulopapillary neoplasms (ITPNs).

Methods: Clinical findings, morphologic features, immunophenotypes and KRAS alterations were investigated in 7 patients with intraductal tubular adenomas, 16 patients with gastric-type intraductal papillary mucinous neoplasms and 6 patients with intraductal tubulopapillary neoplasms.

Results: There were more female patients in the ITA and gastric-type IPMN groups, whereas the opposite pattern was observed in the ITPN group. ITAs and gastric-type IPMNs were lined by columnar cells, similar to pyloric glands, with large extracellular deposits of mucin. ITPNs were polypoid and papillary mass located in the pancreatic ducts, which did not show large deposits of mucin. All ITAs and gastric-type IPMNs expressed MUC5AC strongly and diffusely, and 3/6 ITPNs expressed MUCSAC focally and weakly. KRAS mutations were identified in 4 ITAs (4/7, 57%), 9 IPMNs (9/16, 56%) and 2 ITPNs (2/6, 33%).

Conclusion: The intraductal tubular adenoma should not be considered a precursor lesion of intraductal tubulopapillary neoplasms. No adequate data established ITA should separate as a specific entity from IPMNs.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_172

Keywords: Pancreas, Intraductal tubular adenoma, Pyloric gland adenoma, Intraductal papillary mucinous neoplasm, Intraductal tubulopapillary neoplasm

Background

Due to the application of advanced medical imaging, more and more intraductal lesions of the pancreas are being detected; however, their pathological classification is more complex. The term of intraductal papillary mucinous neoplasm (IPMN) has traditionally been used to describe them, and it is widely recognized. However, some other parallel nomenclatures also exist. In the 2010 edited WHO classification of digestive diseases, intraductal lesions of the pancreas were divided into two types: IPMNs and a new entity termed intraductal tubulopapillary neoplasms (ITPNs) [1].

In 1999, the term ‘pyloric gland adenoma’ was first put forward by Bakotic B.W. as a name for a novel pancreatic intraductal lesion that was distinct from IPMN [2]. Subsequently, 17 cases have been documented in
English literature [2-10] and have been given the name ‘intraductal tubular adenoma’ (pyloric gland-type; ITA). ITAs showed some similarities with IPMNs and ITPNs and also some obvious differences from them.

Besides the WHO classification of intraductal lesions, another system classified intraductal tumors into IPMNs and intraductal tubular neoplasms (ITNs) based on the papillary or tubular structures [11,12]. ITNs were further subclassified into ITAs and intraductal tubular carcinoma (ITCs) depending on the degree of epithelial dysplasia. In this classification, ITA was a precursor lesion to ITC [3,4]. ITC is regarded as a variant of ITPN according to the tubular architectures. Morphologically, ITAs were the benign form and ITPNs were the malignant form. It is doubtful that ITAs may be the precancerous lesion of ITPNs.

The purpose of this study was to report upon a further 7 cases of ITA and to delineate the clinicopathologic characteristics, immunohistochemical features and KRAS mutation rate in these ITAs compared with IPMNs and ITPNs.

Methods

Patients and tissue samples

All selected cases were from Peking Union Medical College Hospital (PUMCH) in 2001–2009 and re-examined by other two senior pathologists. Sixteen cases of gastric-type IPMNs, six cases of ITPNs and seven cases of ITAs were selected. ITAs were diagnosed based on the following definition: a localized polypoid mass within large duct and characterized microscopically by close packing of the tubular pyloric glands. Immunohistochemical staining was performed using the envision method. All ITA, gastric-type IPMN and ITPN cases were stained for MUC1 (Novocastra Laboratories Ltd., clone Ma695, dilution 1:100), MUC2 (Novocastra Laboratories Ltd., clone Ccp58, dilution 1:100) and MUC5AC (Novocastra Laboratories Ltd., clone CLH2, dilution 1:100). Ki-67 (Immunotech S.A., 1:200) and p53 (Novo, DO7, 1:200) staining was also performed. This study was approved by the Ethics Committee of the Peking Union Medical College Hospital, and informed consent was obtained from all cases.

Table 1 The clinical presentations and pathological features of three intraductal neoplasms of pancreas

|                | Gastric-type IPMN | ITA | ITPN |
|----------------|-------------------|-----|------|
| Gender (M/F)   | 10/6              | 5/2 | 2/4  |
| Age (average age) | 39-78 (61)       | 47-74 (58) | 48-70 (64) |
| Site (head/body/tail) | 10/3/3           | 4/3/0 | 4/1/1 |

Clinical features

- Symptoms*: 8/5/3 (abdominal discomfort), 4/2/1 (back pain), 4/1/1 (jaundice)
- Chronic pancreatitis: 5/16
- Diabetes mellitus: 4/16
- Chronic use of tobacco: 6/16
- CA-199 elevated in blood: 5/16
- CEA elevated in blood: 2/16

Pathological features

- Diameter: 1-6 cm, 0.6-3 cm, 1.5-4.5 cm
- Microscopic features: Papillary growth with large mucin, Tubulopapillary growth with mucin, Tubulopapillary growth without luminal mucin

Immunohistochemistry

|                | MUC5AC | MUC1 | MUC2 | Ki-67 index | PS3 | KRAS mutation |
|----------------|--------|------|------|-------------|-----|--------------|
|                | 16/16  | 0/16 | 9/16 | <1%         | -   | 9/16 (56%)    |
|                | 7/7    | 0/7  | 3/7  | 2/7 3-5%    | -   | 4/7 (57%)     |
|                | 3/6    | 3/6  | 0    | >20%        | 3/6 | 2/6 (33%)     |

*From left to right: abdominal discomfort/routine checkup/other symptoms, such as jaundice, back pain, et al.
Most patients complained of abdominal discomfort. Some patients found the pancreatic mass by routine checkup. Some patients of the three groups had a history of chronic pancreatitis and diabetes mellitus. CA19-9 and CEA were occasionally elevated. Comparing with gastric-type IPMNs and ITPNs, the patients of ITAs did not have specific clinical presentations. Computed tomography and B ultrasound revealed pancreatic cystic masses, and the head of pancreas was the most frequently involved site for all three lesions. The common bile duct appeared normal.

Pathological findings
All seven ITAs were well demarcated, and polypoids were located within the cystically dilated ducts (Figure 1A, D), which comprised closely packed ducts or tubular glands that resembled pyloric glands (Figure 1G). Gastric-type IPMNs were papillary and mucin was located in the main and branch ducts (Figure 1B, E). The glands were lined with cuboidal to columnar mucin-secreting cells with abundant cytoplasm and basally oriented nuclei similar to ITAs (Figure 1H). Sporadic goblet cells were observed in some ITAs and gastric-type IPMNs. Mild cell atypia was observed with no obvious hyperchromatic nuclei. Mitotic figures were seldom occurred.

Grossly, ITPNs were located in the large pancreatic ducts and showed polypoid nodules that obstructed the duct (Figure 1C, F); a solid nodule was noted beside the dilated duct in one case. Microscopically, ITPNs were characterized by a tubulopapillary growth pattern without secreted mucin and by back-to-back tubular glands (Figure 1I). The neoplastic cells showed high-grade atypia.

Figure 1 Pathological comparisons between intraductal tubular adenoma (pyloric gland type; A,D,G,J), gastric-type intraductal papillary mucinous neoplasm (IPMN; B, E, H, K) and intraductal tubulopapillary neoplasm (ITPN; C, F, I, L). Grossly, ITA and ITPN show a polypoid and nodular mass in the dilated pancreatic duct (A, C), whereas IPMN shows a papillary mass in the mucin-filled dilated duct (B). Microscopically, ITA and IPMN comprise closely packed ducts or tubular glands that are lined with cuboidal-to-columnar mucin-secreting cells with abundant cytoplasm and basally oriented nuclei (D, E, G, H). ITPN shows tightly-packed small glands with a tubulopapillary growth pattern without secreted mucin (F). The neoplastic cells show high-grade atypia with scant cytoplasmic mucin. Intraductal necrotic foci are observed (I). ITA and IPMN express MUC5AC robustly and diffusely (J, K) and ITPN expresses MUC1.
with scant cytoplasmic mucin. Intraductal necrotic foci were observed frequently.

**Immunohistochemical findings**

All the MUC expression is summarized in Table 1. ITAs and gastric-type IPMNs expressed MUC5AC (Figure 1J, K) but not MUC1 or MUC2, with negative P53 expression and low proliferative index of ki-67. ITPNs were inclined to express MUC1 (Figure 1L) and P53, but not MUC5AC and MUC2, with a high proliferative index.

**KRAS mutations**

KRAS mutations were identified in 4 ITAs (4/7, 57%), 9 IPMNs (9/16, 56%) and 2 ITPNs (2/6, 33%). These mutations all showed a single amino acid substitution in codon 12: Gly12Asp (GGT > GAT) or Gly12Val (GGT > GTT), which are the most common mutational foci in pancreatic carcinomas.

**Discussion**

IPMN is histopathologically subclassified into four subtypes: gastric, intestinal, pancreatobiliary and oncocytic [1]. The majority of gastric-type IPMNs are IPMNs with low-grade dysplasia (IPMN adenoma). There are some similarities that exist between gastric-type IPMNs and ITAs. They are both located in the pancreatic ducts, producing extracellular mucin and causing marked dilation of the ducts. The lining epithelium comprises columnar cells with morphologic, histochemical and immunohistochemical features similar to those of gastric pylorus, immunoreactive to MUC5AC and negative to MUC1 and MUC2, with negative P53 expression.

Intraductal tubule-forming epithelial neoplasm with high-grade dysplasia and ductal differentiation without overt production of mucin [1,13-15]. ITA shows some similarities to ITPN in its histological growth pattern – a tubular pattern with tightly packed small acinar glands. However, from the Table 1, we can see that ITAs were inclined to present in aged men, immunoreactive to MUC5AC and negative for MUC1, whereas ITPNs were inclined to present in aged women, partially negative to MUC5AC and positive for MUC1. The differences in patient population and mucin expression indicate that ITAs and ITPNs are distinct intraductal neoplasms of the pancreas.

**Conclusions**

Intraductal tubular adenoma (ITA) should not be a precursor lesion of ITPN. Up to now, no adequate data established ITA should separate as a specific entity from IPMNs.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

J.C. contributed to the conception of the idea. X.C. and Y.J. carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. J.L. contributed to literature search. All authors read and approved the final manuscript.

**Received:** 29 May 2014 **Accepted:** 23 August 2014

**Published online:** 23 September 2014

**References**

1. Bosman F, Cameofo F, Hruban RH, Theise ND: WHO Classification of Tumors of the Digestive System. 4th edition. Lyon: IARC; 2010:304–313.

2. Bakotic BW, Robinson MJ, Sturm PDJ, Hruban RH, Johan G, Offerhaus A, Albores-Saavedra J: Pyloric gland adenoma of the main pancreatic duct. Am J Surg Pathol 1999, 23:227–231.

3. Albores-Saavedra J, Sheahan K, O’Rain C, Shuha D: Intraductal tubular adenoma, pyloric type, of the pancreas: additional observations on a new type of pancreatic neoplasm. Am J Surg Pathol 2004, 28:233–238.

4. Kato N, Akayama S, Motoyama T: Pyloric gland-type adenoma superimposed on intraductal papillary mucinous tumor of pancreas. Virchows Arch 2002, 440:205–208.

5. Nakayama Y, Inoue H, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Ikiwana S, Tani H, Ryo S, Yasunama Y, Bieda S: Intraductal tubular adenoma of the pancreas, pyloric gland type. Am J Surg Pathol 2005, 29:607–616.
6. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. *Histopathology* 2009, 55:270–276.

7. Amaris J: Intraductal mucinous papillary tumor and pyloric gland adenoma of the pancreas. *Gastrointest Endosc* 2002, 56:441–444.

8. Fukatsu H, Kawamoto H, Tsutsumi K, Kato H, Hirao K, Kurihara N, Ogawa T, Ishida E, Okamoto Y, Okada H, Sakaguchi K, Yanai H: Intraductal tubular adenoma, pyloric gland-type, of the pancreas. *Endoscopy* 2007, 39:E88–E89.

9. Itatsu K, Sano T, Hiraoka N, Ojima H, Takahashi Y, Sakamoto Y, Shimada K, Kosuge T: Intraductal tubular carcinoma in an adenoma of the main pancreatic duct of the pancreas head. *Gastroenterol* 2006, 41:702–705.

10. Nagaie K, Chijiwa K, Hyoshi M, Ohuchida J, Kataoka H: Main-duct intraductal papillary mucinous adenoma of the pancreas with a large mural nodule. *Int J Clin Oncol* 2007, 12:388–391.

11. Huban RH, Pitman MB, Klimstra DS: Tumors of the Pancreas. Washington D.C: American Registry of Pathology; 2007.

12. Japanese Pancreas Society: Classification of Pancreatic Carcinoma, 3rd English edn. Tokyo: Kanehara & Co, Ltd; 2012.

13. Tajiri T, Tate G, Kunimura T, Inoue K, Mitsuya T, Yoshida M, Morohoshi T: Histologic and immunohistochemical comparison of intraductal tubular carcinoma, intraductal papillary-mucinous carcinoma, and ductal adenocarcinoma of the pancreas. *Pancreas* 2004, 29:116–122.

14. Tajiri T, Tate G, Inagaki T, Kunimura T, Inoue K, Mitsuya T, Yoshida M, Morohoshi T: Intraductal tubular neoplasms of the pancreas: histogenesis and differentiation. *Pancreas* 2005, 30:115–121.

15. Maria A, Marco N, Dietmar D, Christain S, Jutta L, Stefan P, Alexander M, Timo G: Case report: intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype. *Diag Pathol* 2014, 9:11. 20 January 2014.

16. Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR, Malesci A: Common occurrence of multiple K-Ras mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. *Oncogene* 2002, 21:4301–4306.

17. Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, Shiratori K, Shibata N, Shimizu M, Funukawa T: The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant. *J Pathol* 2013, 231:335–341.

doi:10.1186/s13000-014-0172-1

Cite this article as: Chang et al.: Intraductal tubular adenomas (pyloric gland-type) of the pancreas: clinicopathologic features are similar to gastric-type intraductal papillary mucinous neoplasms and different from intraductal tubulopapillary neoplasms. *Diagnostic Pathology* 2014 9:172.